AmgenFILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly’s dominance

For years, Novo Nordisk and Eli Lilly have dominated the market of special weight loss drug manufacturers. However, a potential disruptor, Amgen, is on the horizon. Amgen’s experimental obesity medicine, MariTide, is showing significant promise, with potential advantages over its competitors in reducing required doses and prolonging weight reduction. Amgen’s impressive manufacturing capacity further solidifies its position as a superior company, capable of outpacing nimble biotech firms. While Amgen’s shares have risen following promising interim stage study findings, other companies like Viking Therapeutics, Altimmune, Structure Therapeutics, AstraZeneca, and their associates are also making strides in weight loss therapies. These competitors shape the environment in which Amgen operates.

Here is the thing: extremely fierce competition takes place in the market, but demand for the Wegovy and Zepbound of the same market remains the same, as buyers clearly show signs of optimism. According to research, this market will boost to $100 billion by the decade’s close. Even though Amgen is currently in an advantageous situation, experts may specify the time it will take to bring this drug to patients around 2028. Nonetheless, the changing dynamics of the weight loss drug market pinpoint the progressive landscape that creates bottlenecks and opens opportunities for established companies and upcoming stars.

Amgen has a competitive edge.

Amgen’s competitive edge in the weight loss drug market is evident in its study to determine whether MariTide could be administered once a month or even less frequently, offering a more convenient alternative to existing weight loss drugs taken weekly. MariTide demonstrated weight loss maintenance during phase one trials with a single or low dose, suggesting the potential for less frequent dosage regimens. This feature not only enhances the patient experience but also aids manufacturers in their operations, potentially addressing supply issues that Novo Nordisk and Eli Lilly have faced.

A lower dosage frequency of MariTide as part of our treatment may also cause fewer side effects, different from the current treatment, which may cause nausea and vomiting. Some analysts think that injection of some dose monthly or even quarterly could encourage compliance and have a nice effect on patients and, consequently, help achieve desirable weight loss results. In addition, Amgen’s strategy that blocks the GIP hormone receptor and does not activate it as Eli Lilly does with Zepbound is different. It opens the way for a new intricate mechanism for appetite regulation that could have positive results when treating sugar and fat metabolism.

On the one hand, Amgen’s breakthrough in the search for weight-loss drugs has generated exuberance in the financial markets, but on the other hand, other companies are inching toward launching similar drugs. Amgen can capitalize on its submucosal delivery and innovative approach to appetite regulation to be a key disruptor in the weight loss drug market field. Therefore, with such opportunities available for patients and investors, Amgen stands out as promising.

Image by: CNBC

Newer Novo Nordisk Eli Lilly drugs are on the way.

Novo Nordisk and Eli Lilly are close to new drugs for weight loss and diabetes that could be out in the market earlier than similarly positioned products such as Mari’s. The CagriSema development by Novo Nordisk, which consists of semaglutide and cagrilintide compounds administered once a week, already displays promising weight loss results in the second stage of trials, and the late-stage trials will further reveal additional information. At the same time, Eli Lilly’s retatrutide, which takes a variety of hormones into three groups, such as glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon, showed very good results in weight loss in middle stage trials.

Besides that, Eli Lilly Corporation is researching an oral drug called orforglipron, which also targets GLP-1 and is awaiting late-stage clinical evaluation along with retatrutide in 2025. The progress made through these new products reflects the serious interests of both companies in solving the complex problems of obesity and diabetes control, providing an option to existing therapies with improved accessibility and efficacy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Best Auto Finance Center in USA